ORYZON to Provide Corporate Progress Updates at Several Events in February-March

• Keystone Symposia Epigenetic Mechanisms and Cancer Treatment
• Bio-Neuroscience
• 17^th Annual European Life Sciences CEO Forum
• BIO-Europe Spring 2024

MADRID, Spain and BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in February and March.

Oryzon will attend the 2024 Epigenetic Mechanisms and Cancer Treatment conference, organized by Keystone Symposia, which will be held on February 4-7 at the Eldorado Hotel & Spa in Santa Fe, NM (USA). Dr. Tamara Maes, Chairman of Oryzon’s Scientific Advisory Board, will give a presentation entitled “Identifying an Effective Team: Optimizing Combo Treatments With the LSD1 Inhibitor Iadademstat for Oncological Indications” on February 7. Click on the link for more info about Keystone Symposia Epigenetic Mechanisms and Cancer Treatment

Oryzon has been invited to participate at the Bio-Neuroscience conference, which will be held at the Rosarium in Amsterdam (The Netherlands) on February 14-15, where the company will provide a corporate update on its CNS program. Click on the link for more info about Bio-Neuroscience

Oryzon will participate at the 17th Annual European Life Sciences CEO forum, which will take place at the Hilton Zurich Airport Hotel in Zurich (Switzerland) on February 28-29. Oryzon will provide a corporate update and will participate in a panel entitled “Neuro Advances Panel: Highlighting the Main Opportunities” on February 28. Click on the link for more info about the 17^th Annual European Life Sciences CEO forum

Oryzon will attend the BIO-Europe Spring 2024 conference, which will be held at the CCIB in Barcelona (Spain) on March 18-20. The company will hold one-on-one meetings with pharmaceutical companies and global investors. Click on the link for more info about BIO-Europe Spring

About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS and iadademstat in oncology, in several Phase II clinical trials. The company has other pipeline assets directed against other epigenetic targets like HDAC-6, where ORY-4001 has been nominated as clinical candidate for the treatment of certain neurological disorders such as CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit www.oryzon.com